The Study, Led by the University Hospital of Nice, France Involves 30,000 Patients Tech2Heal’s Platform has been chosen as the technological backbone for the Study 3.4million Europeans live in assisted-care facilities, and 101million are 65 […]
TORONTO, ON /March 6, 2023 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to report that its wholly owned subsidiary, Health […]
TORONTO, ON / February 2, 2023 / AI/ML Innovations Inc. (“AIML”) (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce that its minority-owned […]
Teladoc Health (NYSE: TDOC) Earnings Call Q3 2022 Highlights CEO Jason Gorevic: Teladoc Health reported strong third quarter results driven by solid execution across the business. Revenue grew 17% over the prior years to […]
The human study will evaluate the Company’s proprietary psilocybin drug (NM-1001) in the treatment of Fragile X Syndrome Vancouver, British Columbia–(Newsfile Corp. – December 22, 2022) – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) […]
Microdose Treatment Modulates Cognition Vancouver, British Columbia— December 8, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and […]
Microdose Psilocybin Safety and Efficacy Clinical Study in Fragile X Syndrome Vancouver, British Columbia– November 30, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and […]
NEXT SUPER STOCK: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.: “Nova’s Psilocybin-based Therapeutics Showing Vast Potential for Autism and Other Neuroinflammatory Disorders” 9/7/22 NEXT SUPER STOCK: Nova Mentis Life Sciences […]
Vancouver, British Columbia-November 17, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) (FSE: HN3Q) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders […]
Company Plans to Submit Clinical Trial Application in Canada Vancouver, British Columbia— September 15, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader […]
– Alakin to be utilized in a Parkinson study set to commence in Paris, France – TORONTO, ON / August 2, 2022 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine […]
Vancouver, British Columbia- – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased […]
11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months 6 of 17 patients (35.2%) achieved a complete renal response, including a […]
Vancouver, British Columbia–June 22, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders […]
TORONTO, ON / June 22, 2022 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce that its minority-owned subsidiary, Tech2Heal […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
